OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-12.26%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$277M
AUM Growth
+$277M
(-16%)
Cap. Flow
+$6.82M
Cap. Flow
% of AUM
2.47%
Top 10 Holdings %
Top 10 Hldgs %
42.56%
Holding
60
New
17
Increased
8
Reduced
14
Closed
11
Top Buys
| 1 |
Stereotaxis
STXS
|
$14.3M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$10.8M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$8.04M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$4.79M |
| 5 |
Quanterix
QTRX
|
$4.06M |
Top Sells
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$9.31M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$6.35M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$5.75M |
| 4 |
Arvinas
ARVN
|
$4.84M |
| 5 |
Viking Therapeutics
VKTX
|
$3.32M |
Sector Composition
| 1 | Healthcare | 97.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWAV
26
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $4.79M | 1.73% |
+160,000
| New | +$4.79M |
|
27
Zymeworks
ZYME
$1.07B
| $4.22M | 1.52% |
170,000
| – | – |
|
|
28
Quanterix
QTRX
$202M
| $4.06M | 1.47% |
+185,000
| New | +$4.06M |
|
29
Dianthus Therapeutics
DNTH
$781M
| $3.95M | 1.43% |
385,000
-150,000
| -28% | -$1.54M |
|
30
TG Therapeutics
TGTX
$5.03B
| $3.44M | 1.24% |
612,500
-537,500
| -47% | -$3.02M |
|
|
RARX
31
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $3.35M | 1.21% |
141,800
+90,800
| +178% | +$2.15M |
|
32
Crinetics Pharmaceuticals
CRNX
$3.26B
| $3.11M | 1.13% |
207,000
+171,000
| +475% | +$2.57M |
|
|
THOR
33
DELISTED
Synthorx, Inc. Common Stock
THOR
| $2.93M | 1.06% |
180,000
+22,400
| +14% | +$364K |
|
34
Neurogene
NGNE
$284M
| $2.84M | 1.03% |
+995,000
| New | +$2.84M |
|
|
FTSV
35
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $2.73M | 0.99% |
+425,000
| New | +$2.73M |
|
36
NextCure
NXTC
$13.3M
| $2.62M | 0.95% |
+85,000
| New | +$2.62M |
|
|
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
| $1.93M | 0.7% |
+75,000
| New | +$1.93M |
|
|
APTO
38
DELISTED
Aptose Biosciences, Inc.
APTO
| $1.5M | 0.54% |
+720,000
| New | +$1.5M |
|
|
FLXN
39
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $1.44M | 0.52% |
+105,000
| New | +$1.44M |
|
|
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.36M | 0.49% |
+200,000
| New | +$1.36M |
|
|
EDAP
41
EDAP TMS
EDAP
$103M
| $1.35M | 0.49% |
+300,000
| New | +$1.35M |
|
|
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.27M | 0.46% |
+170,000
| New | +$1.27M |
|
|
SBBP
43
DELISTED
Strongbridge Biopharma plc.
SBBP
| $1.17M | 0.42% |
490,000
-650,000
| -57% | -$1.55M |
|
|
CBAY
44
DELISTED
Cymabay Therapeutics
CBAY
| $717K | 0.26% |
+140,000
| New | +$717K |
|
|
VRML
45
DELISTED
Vermillion, Inc.
VRML
| $661K | 0.24% |
1,265,000
-2,985,000
| -70% | -$1.56M |
|
46
Assembly Biosciences
ASMB
$183M
| $492K | 0.18% |
+50,000
| New | +$492K |
|
|
BLRX
47
BioLineRX
BLRX
$15.5M
| $44K | 0.02% |
16,667
-233,333
| -93% | – |
|
48
Protara Therapeutics
TARA
$125M
| $14K | 0.01% |
+54,000
| New | +$14K |
|
|
ARQL
49
DELISTED
Arqule Inc
ARQL
| – | – |
-100,000
| Closed | -$1.1M |
|
|
AIMT
50
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| – | – |
-130,000
| Closed | -$2.71M |
|